These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 23428786)
1. Clinical aspects of comorbid schizophrenia and idiopathic Parkinson's disease. de Jong MH; Zemel D; Van Gool AR Clin Schizophr Relat Psychoses; 2014 Apr; 8(1):36-40. PubMed ID: 23428786 [TBL] [Abstract][Full Text] [Related]
2. Comorbidity of parkinsonism and schizophrenia in a patient treated with clozapine. Urban A; Libiger J; Hosák L; Kupka K Eur Psychiatry; 2003 Aug; 18(5):258-9. PubMed ID: 12927328 [TBL] [Abstract][Full Text] [Related]
3. Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease. Martínez-Martín P; Hernández B; Ricart J; Neurologia; 2014 Apr; 29(3):153-60. PubMed ID: 23465686 [TBL] [Abstract][Full Text] [Related]
4. Treatment dilemma in comorbidity of schizophrenia and idiopathic Parkinson's disease. Lan CC; Su TP; Chen YS; Bai YM Gen Hosp Psychiatry; 2011; 33(4):411.e3-5. PubMed ID: 21762841 [TBL] [Abstract][Full Text] [Related]
5. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone. Reichmann H; Emre M Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667 [TBL] [Abstract][Full Text] [Related]
6. Idiopathic Parkinson's disease in a chronic schizophrenic patient: long-term treatment with clozapine and L-dopa. Friedman JH; Max J; Swift R Clin Neuropharmacol; 1987 Oct; 10(5):470-5. PubMed ID: 3503685 [No Abstract] [Full Text] [Related]
7. [The use of stalevo in the treatment of patients with Parkinson's disease]. Kretova AS; Lyubimov AV Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(10):35-8. PubMed ID: 25591514 [TBL] [Abstract][Full Text] [Related]
8. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. Fung VS; Herawati L; Wan Y; ; Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551 [TBL] [Abstract][Full Text] [Related]
9. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Hauser RA; Panisset M; Abbruzzese G; Mancione L; Dronamraju N; Kakarieka A; Mov Disord; 2009 Mar; 24(4):541-50. PubMed ID: 19058133 [TBL] [Abstract][Full Text] [Related]
11. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A; Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632 [TBL] [Abstract][Full Text] [Related]
12. [Stalevo (levodopa/carbidopa/entacapon)--a new generation drug in the treatment of Parkinson's disease]. Fedorova NV; Levin OS; Smolentseva IG; Kulua TK Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):39-46. PubMed ID: 17069061 [TBL] [Abstract][Full Text] [Related]
13. [Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study]. Liashchenko EA; Skripkina NA; Levin OS Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):62-8. PubMed ID: 23994933 [TBL] [Abstract][Full Text] [Related]
14. [Idiopathic Parkinson's disease: practical hints for the treatment]. Ludin HP Praxis (Bern 1994); 2005 Jul; 94(30-31):1147-50. PubMed ID: 16117469 [TBL] [Abstract][Full Text] [Related]
15. Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study. Tinazzi M; Morgante F; Matinella A; Bovi T; Cannas A; Solla P; Marrosu F; Nicoletti A; Zappia M; Luca A; Di Stefano A; Morgante L; Pacchetti C; Minafra B; Sciarretta M; Dallocchio C; Rossi S; Ulivelli M; Ceravolo R; Frosini D; Cipriani A; Barbui C Schizophr Res; 2014 Feb; 152(2-3):344-9. PubMed ID: 24369987 [TBL] [Abstract][Full Text] [Related]
16. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease. Ishihara A; Miyachi T; Nakamura T; Ohtsuki T; Kimura Y; Kihira K; Yamawaki T; Matsumoto M Hiroshima J Med Sci; 2011 Sep; 60(3):57-62. PubMed ID: 22053701 [TBL] [Abstract][Full Text] [Related]
17. Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients. Nevrly M; Kanovsky P; Vranova H; Langova K; Hlustik P Parkinsonism Relat Disord; 2009 Jul; 15(6):477-8. PubMed ID: 19028438 [No Abstract] [Full Text] [Related]
18. [Nocturnal motor symptoms of Parkinson's disease and their treatment with the three-component drug levodopa/carbidopa/entacapone]. Kulua TK; Fedorova NV; Popovkina OA Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(9 Pt 2):45-50. PubMed ID: 22027607 [TBL] [Abstract][Full Text] [Related]
19. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Stocchi F; Hsu A; Khanna S; Ellenbogen A; Mahler A; Liang G; Dillmann U; Rubens R; Kell S; Gupta S Parkinsonism Relat Disord; 2014 Dec; 20(12):1335-40. PubMed ID: 25306200 [TBL] [Abstract][Full Text] [Related]